EUCTR2006-006154-97-IT进行中（未招募）不适用
HEMOS ALL 0105 Intensification therapy of mature B-ALL, Burkitt and Burkitt like and other HIgh Grade Non-Hodgkin?s Lymphoma in Adults - HEMOS ALL 1105
AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI0 个研究点开始时间: 2007年5月15日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •? Mature B-cell-ALL (L3-ALL)
- •? High-grade non-Hodgkin's lymphoma of the following subtypes
- •(WHO classification)
- •- Burkitt?s lymphoma (incl. atypical Burkitt?s lymphoma)
- •- Precursor B-lymphoblastic lymphoma
- •- Anaplastic large-cell lymphoma (Ki1+, B-, T- or Null-cell type) -
- •Mediastinal large B-cell lymphoma (subtype of diffuse large B-Cell
- •? Age = 18 years
- •? Patient?s Informed Consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Serious secondary diseases including psychiatric conditions, under
- •which the required therapy compliance is not to be expected
- •? HIV infection
- •? Secondary lymphoma following prior chemotherapy/radiotherapy or an
- •active second malignancy
- •? Known severe allergy to foreign proteins
- •Pre-treatment (Exception: 1 cycle CHOP or similar, < 1 week of another chemotherapy)
- •Pregnancy or nursing
- •? Absence of patient?s written informed consent
- •? Participation in other studies that interfere with the study therapy
研究者
相似试验
尚未招募
不适用
Intensification of treatment in people with an obsessive compulsive disorder who do not recover sufficiently from regular ERP treatment: a stepped care approachObsessive compulsive disorder10002861NL-OMON56782HSK Groep35
Unknown
4 期
Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in AdultsNon-Hodgkin's LymphomaAcute Lymphoblastic LeukemiaNCT00797810University of Bologna25
招募中
1 期
CAR-T-cell treatment for untreated high risk MANtle Cell LymphomaMantle Cell Lymphoma (MCL)MedDRA version: 21.0Level: PTClassification code: 10026805Term: Mantle cell lymphoma stage IV Class: 100000004864MedDRA version: 21.0Level: PTClassification code: 10026803Term: Mantle cell lymphoma stage II Class: 100000004864MedDRA version: 21.0Level: PTClassification code: 10026804Term: Mantle cell lymphoma stage III Class: 100000004864CTIS2022-502405-15-01Klinikum Der Universitat Munchen AöR91
已完成
不适用
Treatment intensification based on disease activity parameters or on cartilage breakdown markers in early rheumatoid arthritisRheumatoid arthritisISRCTN96372677Vrije University Medical Centre (VUMC) (The Netherlands)40
进行中（未招募）
1 期
Treatment with two drugs, Dasatinib and Blinatumomab, for the patients with a form of cancer which affects the cells which give origin to white cells (cells present in blood) who have not been treated previously with other drugs for this pathology.Acute Lymphoblastic Leukemia Philadelphia Chromosome Positive (Ph+)MedDRA version: 21.0Level: LLTClassification code 10000844Term: Acute lymphoblastic leukaemiaSystem Organ Class: 100000004864EUCTR2016-001083-11-ITFONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS63